Research programme: DEAD-box RNA helicase inhibitors - Lead Discovery Siena
Alternative Names: DDX3 inhibitors - Lead Discovery SienaLatest Information Update: 28 Oct 2022
At a glance
- Originator University of Siena
- Developer Lead Discovery Siena
- Class Antineoplastics; Small molecules
- Mechanism of Action DEAD-box RNA helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for research development in Cancer in Italy
- 05 Sep 2018 DEAD-box RNA helicase inhibitors - Lead Discovery Siena is available for licensing as of 05 Sep 2018. http://leaddiscoverysiena.it/ (Lead Discovery Siena website, September 2018)
- 05 Sep 2018 Early research in Cancer in Italy (unspecified route) prior to September 2018 (Lead Discovery Siena website, September 2018)